Receive support during Itovebi treatment at no cost to you

Are you seeking treatment support?

Your Nurse Educator will:

Medication icon

Explain what to expect when you're starting treatment

Potential side effects icon

Tell you about potential side effects and tips that may help

Question mark icon

Answer questions, in English or Spanish, throughout your treatment journey

Educational material is also available via email from Genentech.

If you need help signing up, support is available from the Patient Resource Center at 1 (877) GENENTECH (436-3683) Monday-Friday, 6 AM-5 PM PT.

Are you seeking financial support?

If you are looking for ways to help you afford your medicine, consider signing up for Itovebi Access Solutions. Once you sign up, an Itovebi Case Manager can help you understand your insurance and may be able to find potential financial assistance options, if you are eligible.

Meet your Nurse Educators

Providing one-on-one virtual, personalized education sessions—just for you

Nurse educator profile picture 1

Stephanie

Combining her deep expertise as an oncology nurse practitioner with the compassion to address patients' concerns, Stephanie ensures every patient feels empowered and understood throughout their treatment journey.

Nurse educator profile picture 2

Pamela

As an oncology nurse and cancer survivor, Pamela draws on over a decade of experience to bring unique insight to patient education, answering questions with care and ensuring patients feel empowered and prepared for treatment.

Nurse Educators are representatives of Genentech and do not give medical advice. Please contact your healthcare provider if you experience side effects or need medical advice. A Nurse Educator can help with additional support and tips.

How to get started with your education sessions

Sign up icon

1. Sign up

Receive a call, text, or voicemail icon

2. Receive a call, text, or voicemail

  • An Itovebi Nurse Educator will contact you within 2 business days of signing up
  • Keep an eye out for a communication from “Nurse Educator.” If you opted to receive a call, it may be from an unknown number
Schedule your sessions icon

3. Schedule your sessions

  • Feel free to include family members or caregivers in your virtual sessions

Sign up for education and support

*Indicates a required field.

Which best describes you?*
I am a:*

Your email address and phone number are required to participate in this optional and free patient support program.

By submitting this form, I am requesting disease education and/or other materials from and on behalf of Genentech and its affiliates. This may include information about products and services, including co-pay assistance or other patient support, opportunities to participate in surveys or provide feedback, or other topics. I understand that my personal information, which may include sensitive information, will be used and disclosed as described in Genentech’s Privacy Policy and that I may be contacted using the information I have provided. I understand providing this agreement is voluntary and plays no role in getting my medicine, and that I may opt out of receiving this information at any time by calling 877-436-3683. By submitting this form, I confirm that I am 18 years of age or older and that I agree to the Terms & Conditions.

Thank you for your interest

Patient support is only available to people receiving treatment with Itovebi. If you’d like more information about the patient support services Genentech offers, click here.

Thank you for signing up!

Your request has been received.

One of our Itovebi Nurse Educators will contact you within 2 business days to schedule your personalized education session(s).

You’ll receive a call, text, or voicemail from “Nurse Educator”—please keep an eye out so we can connect with you soon.

If you have any immediate questions about your treatment, please contact your healthcare provider.

Patient brochure CTA image

UNDERSTANDING YOUR TREATMENT

What to expect, where to find support, and more

CTA image of patient holding Itovebi tablet

STEPS TO MANAGE HYPERGLYCEMIA

Learn what you need to do to get the most out of treatment

Financial support CTA image

FINANCIAL SUPPORT

Learn about options that may be available to help you afford your Itovebi

Important Safety Information & Use

What is Itovebi?

Itovebi® (inavolisib) is a prescription medicine used in combination with the medicines palbociclib and fulvestrant to treat adults who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has an abnormal phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA) gene, and has spread to nearby tissue or lymph nodes (locally advanced), or to other parts of the body (metastatic), and has come back after hormone (endocrine) therapy.

Your healthcare provider will test your cancer for abnormal PIK3CA genes to make sure that Itovebi is right for you.

It is not known if Itovebi is safe and effective in children.

What are the possible side effects of Itovebi?

Itovebi may cause serious side effects, including:

  • High blood sugar levels (hyperglycemia). High blood sugar is common with Itovebi and may be severe or fatal. Untreated severe hyperglycemia can lead to a condition called diabetic ketoacidosis that can happen in people treated with Itovebi. Diabetic ketoacidosis is a serious condition that requires treatment in a hospital and that can lead to death. Your healthcare provider will monitor your blood sugar levels before you start and during treatment with Itovebi. Your blood sugar levels may be monitored more often if you have a history of Type 2 diabetes. Your healthcare provider may also ask you to self-monitor and report your blood sugar levels at home. This will be required more frequently in the first 4 weeks of treatment. If you are not sure how to test your blood sugar levels, talk to your healthcare provider. You should stay well-hydrated during treatment with Itovebi. Tell your healthcare provider right away if you develop symptoms of high blood sugar, including:

    • difficulty breathing
    • nausea and vomiting (lasting more than 2 hours)
    • stomach pain
    • excessive thirst
    • dry mouth
    • more frequent urination than usual or a higher amount of urine than normal
    • blurred vision
    • unusually increased appetite
    • weight loss
    • fruity-smelling breath
    • flushed face and dry skin
    • feeling unusually sleepy or tired
    • confusion
  • Mouth sores (stomatitis). Mouth sores are common with Itovebi and may be severe. Tell your healthcare provider if you develop any of the following in your mouth:
    • pain
    • redness
    • swelling
    • ulcers
  • Diarrhea. Diarrhea is common with Itovebi and may be severe. Severe diarrhea can lead to the loss of too much body water (dehydration) and kidney injury. Tell your healthcare provider right away if you develop diarrhea, stomach-area (abdominal) pain, or see mucus or blood in your stool during treatment with Itovebi. Your healthcare provider may tell you to drink more fluids or take medicines to treat your diarrhea.

Your healthcare provider may tell you to decrease your dose, temporarily stop your treatment, or completely stop your treatment with Itovebi if you develop certain serious side effects.

The most common side effects and abnormal blood test results of Itovebi when used in combination with palbociclib and fulvestrant include:

  • decreased white blood cell counts, red blood cell counts, and platelet counts
  • decreased blood levels of calcium, potassium, sodium, and magnesium
  • increased creatinine blood levels
  • tiredness
  • increased blood levels of the liver enzyme alanine transaminase (ALT)
  • nausea
  • rash
  • loss of appetite
  • COVID-19 infection
  • headache

Itovebi may affect fertility in males and in females who are able to become pregnant. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of Itovebi. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (877) 436-3683.

Before you take Itovebi, tell your healthcare provider about all of your medical conditions, including if you:

  • have a history of diabetes or high blood sugar
  • have kidney problems
  • are pregnant or plan to become pregnant. Itovebi can harm your unborn baby.
    Females who are able to become pregnant:
    • Your healthcare provider will check to see if you are pregnant before you start treatment with Itovebi.
    • You should use effective non-hormonal birth control (contraception) during treatment with Itovebi and for 1 week after your last dose. Talk to your healthcare provider about what birth control method is right for you during this time.
    • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Itovebi.
    Males with female partners who are able to become pregnant:
    • You should use effective birth control (contraception) during treatment with Itovebi and for 1 week after your last dose.
  • are breastfeeding or plan to breastfeed. It is not known if Itovebi passes into your breastmilk. Do not breastfeed during treatment with Itovebi and for 1 week after your last dose. Talk to your healthcare provider about the best way to feed your baby during treatment with Itovebi.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see the full Prescribing Information, including Patient Information, for additional Important Safety Information.

  • PI3K

    A type of protein that transmits signals in cells and is involved in cell growth

  • Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)

    A gene that helps make the PI3K protein. Mutations in the PIK3CA gene may cause PI3K to become overactive, which may make cancer cells grow

+